This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
This investment will provide West with access to NanoPass' knowledge and expertise in the growing area of intradermal drug delivery and future collaboration opportunities to bring new products to market. West's investment will also allow NanoPass to advance its clinical development efforts and support the launch of its microneedle-based device for intradermal delivery of vaccines and drugs.
"We expect that advances in intradermal drug delivery will be critical to realizing the full potential of some of the pharmaceutical and biotechnology industry's latest advancements in immunotherapy treatments," said Eric Resnick, Vice President and Chief Technology Officer, Innovation and Technology, West. "The microneedle technology developed by NanoPass complements our growing portfolio of drug delivery solutions at West, including our own Intradermal Adapter. We believe NanoPass has made great strides in this specialized area of drug delivery and we look forward to our partnership."
"We are delighted to enter into this strategic partnership with West, a recognized global leader in the integrated containment and delivery of injectable drugs," said Dr. Yotam Levin, Chief Executive, NanoPass. "We share a vision of enabling new vaccines, cancer and allergy immunotherapies with our intradermal injection technology, and envision significant synergies in production, marketing and future device developments. We could not have found a more suitable partner with the global reach, capacity and related expertise to grow NanoPass to the next level."
